Phillips Alisa L, Li Cai, Liang Jia, Sheyn Anthony, Rastatter Jeffrey C, Chelius Daniel C, Orbach Daniel, Richard Celine
University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee, USA.
Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Pediatr Blood Cancer. 2024 May;71(5):e30928. doi: 10.1002/pbc.30928. Epub 2024 Feb 28.
This study aims to analyze the behavior and treatment of adenoid cystic carcinoma (AdCC) in the pediatric and young adult population and to identify factors affecting overall survival (OS).
The study analyzed salivary gland malignancies in patients aged 0-21 with AdCC histology using the National Cancer Database from 2004 to 2018.
A total of 72 patients (59.7% parotid, 36.1% submandibular, 1.4% sublingual, 2.8% unspecified) met criteria. Median age was 18 years [range: 0-21]. High-grade dysplasia was present in 67% of cases. Therapy consisted of primary surgery for all cases, regional lymph node dissection (LND) (74%), radiotherapy (71%), chemotherapy (8%), and chemoradiation (7%). The 5-year OS rate was 93.2% [95% confidence interval (CI): 86.9%-99.9%], respectively. Patients who underwent associated LND had improved OS (p = .0083, log-rank test) with a 5-year OS at 82.4% [95% CI: 66.1%-100%] versus 97.6% [95% CI: 93.0%-100%]. A significant difference in OS was found with unfavorable outcomes after positive marginal status: 5-year OS 84.1% [95% CI: 71.0%-99.7%] versus 100% [95% CI: 100%]; p < .001. Adjuvant therapy did not seem to impact the outcome.
This study confirms that AdCC in children and young adults has an overall good prognosis despite frequent high grade. It suggests that cervical LND may be of importance, but the value of systematic adjuvant therapy is not confirmed. These findings emphasize the importance and relevance of population-based studies in shaping clinical practice and informing the design of future prospective investigations.
本研究旨在分析儿童及青年人群腺样囊性癌(AdCC)的行为及治疗情况,并确定影响总生存期(OS)的因素。
本研究使用2004年至2018年的国家癌症数据库,分析了年龄在0至21岁、组织学为AdCC的涎腺恶性肿瘤患者。
共有72例患者(59.7%为腮腺,36.1%为下颌下腺,1.4%为舌下腺,2.8%未明确)符合标准。中位年龄为18岁[范围:0至21岁]。67%的病例存在高级别发育异常。所有病例的治疗均包括初次手术、区域淋巴结清扫(LND)(74%)、放疗(71%)、化疗(8%)及放化疗(7%)。5年总生存率分别为93.2%[95%置信区间(CI):86.9% - 99.9%]。接受相关LND的患者总生存期有所改善(p = 0.0083,对数秩检验),5年总生存率为82.4%[95% CI:66.1% - 100%],而未接受LND的患者为97.6%[95% CI:93.0% - 100%]。切缘阳性后出现不良预后,总生存期存在显著差异:5年总生存率为84.1%[95% CI:71.0% - 99.7%],而切缘阴性者为100%[95% CI:100%];p < 0.001。辅助治疗似乎并未影响预后。
本研究证实,儿童及青年的AdCC尽管常有高级别病变,但总体预后良好。提示颈部LND可能具有重要意义,但系统性辅助治疗的价值尚未得到证实。这些发现强调了基于人群的研究在塑造临床实践及为未来前瞻性研究设计提供信息方面的重要性和相关性。